Saturday 17 October 2026 Export APRE’s income statement to Excel — free account

Aprea Therapeutics, Inc.

Aprea Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $285,800.00, down 81.0% from fiscal 2024. In the quarter to June 2026, revenue fell 98.4%, EPS grew 86.8% and free cash flow fell 5.22%, each against the same quarter a year earlier. Insiders bought in the last twelve months.

0.58 0.04 −6.45%

Follow APRE

Alert me

Market cap: $7.8M
P/E: 0.0×
Fwd P/E: −1.0×
Dividend yield: —
F-score: 1/9
Altman Z: −30.12
Beneish M: n/a
Dividend safety: n/a

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Total buys 0.06

Totals in millions of $.

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	—	2	2	—	—	—	—	—	—	—	—	—
Sell	—	—	—	—	—	—	—	—	—	—	—	—

Insider Ownership 78.57%

Capital & Financial Ratios $m

Market Cap 7.78

Revenue 0.29

Net Income (12.31)

Free Cash Flow (12.19)

Net Debt (41.23)

Current Ratio 13.55

Debt/Equity 0.00

P/E ratio 0.00

Fwd P/E (0.95)

P/S ratio 108.58

P/B ratio 0.81

Past 5Y EPS Growth —

This Y EPS Growth 83.55%

Next Y EPS Growth (11.02%)

Next Y revenue growth 42.93%

Next 5Y EPS Growth 43.58%

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years

P/B against its own 10 years 45.80%

10-year low 10-year high

EV/FCF against its own 10 years 78.09%

10-year low 10-year high

Dividends

Payout Ratio —

Annual Dividend Rate —

Annual Dividend Yield —

	total	individual payouts
2023	Powerpack
2022	Powerpack
2021	Powerpack
2020	Powerpack
2019	Powerpack

special payouts not included in total or ratios

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	22	23	15	41
Receivables	—	—	—	—
Inventory	—	—	—	—
Other	—	—	—	—
	23	24	16	42

	2023	2024	2025	Q'26
Payables	2	1	1	1
ST’ Debt	—	—	—	—
Other	—	—	—	—
	4	3	3	3

Compound Annual Growth %

	10y	5y	3y
Sales	—	—	—
Cash Flow	—	0.00%	0.00%
Earnings	—	0.00%	0.00%
Book Value	—	(30.62%)	(21.42%)

Revenue $m

	Mar	Jun	Sep	Dec	Year
’26	—	—	—	—	—
’25	0	0	0	0	0
’24	0	1	0	0	2

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(3)	(3)	—	—	—
’25	(4)	(3)	(3)	(3)	(13)
’24	(4)	(4)	(2)	(4)	(14)
’23	(3)	(3)	(2)	(4)	(12)
’22	(5)	(9)	(7)	(4)	(25)
’21	(12)	(8)	(8)	(10)	(38)
’20	(8)	(10)	(11)	(13)	(42)

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(3)	(3)	—	—	—
’25	(4)	(3)	(3)	(3)	(13)
’24	(4)	(4)	(2)	(4)	(14)
’23	(3)	(3)	(2)	(4)	(12)
’22	(5)	(9)	(7)	(4)	(25)
’21	(12)	(8)	(8)	(10)	(38)
’20	(8)	(10)	(11)	(13)	(42)

Fiscal quarters ending in the months shown.

EPS $

	Mar	Jun	Sep	Dec	Year
’26	(0.22)	(0.07)	—	—	—
’25	(0.66)	(0.53)	(0.47)	(0.32)	(1.93)
’24	(0.67)	(0.58)	(0.64)	(0.49)	(2.35)
’23	(1.34)	(0.87)	(0.86)	(0.92)	(3.95)
’22	(7.20)	(86.80)	(2.40)	(0.92)	(67.99)
’21	(9.20)	(9.60)	(9.00)	(7.20)	(34.80)
’20	(9.00)	(15.60)	(11.60)	(14.60)	(50.60)

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026e
Price, $
Price, $	Low	—	—	—	302.00	94.60	55.76	6.08	0.47	2.15	0.84	Analyst estimates 2026–2028 Powerpack
	High	—	—	—	1,062.20	920.00	169.20	64.20	12.00	8.85	5.00
People
People	Employees	—	—	14	13	17	16	9	7	8	8
	Revenue/emp, $m	—	—	0.00	0.00	0.00	0.00	0.00	0.08	0.19	0.04
Income, $m
Income, $m	Revenue	—	—	—	—	—	—	—	1	2	0
	Gross margin, %	—	—	—	—	—	—	—	100.00	100.00	100.00
	EBT	—	(15)	(16)	(28)	(53)	(37)	(113)	(14)	(13)	(13)
	EBT margin, %	—	0.00	0.00	0.00	0.00	0.00	0.00	(2,449.73)	(862.42)	(4,408.54)
	Net income	—	(15)	(16)	(28)	(53)	(37)	(113)	(14)	(13)	(13)
	Depreciation	—	0	0	0	0	0	0	0	0	0
Per share, $
Per share, $	Revenue	—	0.00	0.00	0.00	0.00	0.00	0.00	0.16	0.27	0.04
	Earnings	—	(263.49)	(269.12)	(93.40)	(50.60)	(34.80)	(67.99)	(3.95)	(2.35)	(1.93)
	Cash flow	—	(242.67)	(264.30)	(89.00)	(39.55)	(35.41)	(15.09)	(3.37)	(2.46)	(1.97)
	Capex	—	0.00	(0.06)	(0.10)	(0.02)	0.00	0.00	(0.03)	0.00	0.00
	Free cash flow	—	(242.67)	(264.37)	(89.10)	(39.57)	(35.41)	(15.09)	(3.39)	(2.46)	(1.97)
	Book value	—	0.00	1,059.87	414.01	73.22	46.52	15.48	4.69	3.50	1.90
	Shares, m	—	0	0	0	1	1	2	4	6	7
Valuation, ×
Valuation, ×	P/E	—	—	—	—	—	—	—	0.00	0.00	0.00
	P/S	—	—	—	—	—	—	—	0.00	12.06	19.45
	P/B	—	—	—	—	—	—	—	1.07	0.94	0.45
	EV/Sales	—	—	—	—	—	—	—	0.00	(3.14)	(31.65)
	EV/FCF	—	—	—	—	—	—	—	0.29	0.35	0.70
Cash, $m
Cash, $m	Operating cash flow	—	(14)	(15)	(27)	(42)	(38)	(25)	(12)	(14)	(13)
	Capex	—	—	0	0	0	—	—	0	0	—
	Free cash flow	—	(14)	(15)	(27)	(42)	(38)	(25)	(12)	(14)	(13)
Balance, $m
Balance, $m	Working capital	—	—	61	124	77	49	27	18	20	13
	Total debt	—	—	—	1	—	—	—	—	—	—
	Net debt	—	—	(66)	(130)	(89)	(53)	(29)	(22)	(23)	(15)
	Shareholders’ equity	—	—	61	124	77	50	26	17	19	12
Returns, %
Returns, %	ROA	—	(46.02)	(47.04)	(28.11)	(47.24)	(49.63)	(259.05)	(54.11)	(55.58)	(63.14)
	ROIC	—	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	ROE	—	0.00	(42.66)	(77.08)	(53.04)	(58.51)	(299.83)	(67.08)	(71.47)	(79.37)

Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2025 · latest quarter Dec 2025

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
SNTI Senti Biosciences, Inc.	$8.1M	— (loss-making)	— (loss-making)	−98.68% (below 0%: shrinking)	n/m	−7.48% (below 0%: shrinking)	100.00%	(85,229.41%)	Compare
QNRX Quoin Pharmaceuticals, Ltd. Sponsored ADR	$8.1M	— (loss-making)	—	—	n/m	−510.28% (below 0%: shrinking)	0.00%	0.00%	Compare
XTLB XTL Biopharmaceuticals Ltd.	$8.1M	— (loss-making)	—	−39.32% (below 0%: shrinking)	n/m	+46.78% (above 0%: growing)	0.00%	0.00%	Compare
KPTI Karyopharm Therapeutics Inc.	$8.0M	— (loss-making)	— (loss-making)	−11.86% (below 0%: shrinking)	n/m	−33.34% (below 0%: shrinking)	96.75%	(67.38%)	Compare
CNSP CNS Pharmaceuticals, Inc.	$7.9M	— (loss-making)	—	—	n/m	+33.70% (above 0%: growing)	0.00%	0.00%	Compare
APRE Aprea Therapeutics, Inc.	$7.8M	— (loss-making)	— (loss-making)	−98.40% (below 0%: shrinking)	n/m	−5.22% (below 0%: shrinking)	100.00%	0.00%
SNGX Soligenix Inc.	$7.7M	— (loss-making)	— (loss-making)	−98.89% (below 0%: shrinking)	n/m	+37.83% (above 0%: growing)	0.00%	0.00%	Compare
CURX Curanex Pharmaceuticals Inc	$7.6M	— (loss-making)	—	—	n/m	−272.32% (below 0%: shrinking)	—	0.00%	Compare
MBRX Moleculin Biotech, Inc.	$7.6M	0.0×	—	—	n/m	−19.26% (below 0%: shrinking)	0.00%	0.00%	Compare
Median of peers	$7.9M	—	—	−69.00%	—	−13.37%	0.00%	0.00%

All 614 Biotechnology stocks →

Aprea Therapeutics, Inc. (APRE) key facts

Concern: Aprea Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $285,800.00, down 81.0% from fiscal 2024.
Aprea Therapeutics, Inc. (APRE) is a Biotechnology company in the Healthcare sector, listed on Nasdaq.
As of October 16, 2026, APRE traded at $0.58, a market capitalization of $7.8 million.
Return on equity was −79.4% and debt-to-equity 0.00.
Its Piotroski F-score is 1 out of 9 and its Altman Z-score is −30.12 (distress zone) for fiscal 2025.

Source: company filings (standardised) and stockrow calculations.